Pharma
-
With MS & Fibrosis Trials Planned, J&J-Partnered Contineum Now Preps for IPO
Contineum Therapeutics, which emerged from a Verant Ventures startup creation engine, has filed paperwork for an IPO. The biotech’s clinical-stage pipeline spans multiple sclerosis, idiopathic pulmonary fibrosis, and depression.
-
Creating an Omnichannel Customer Journey in Healthcare
Improving Customer Experience and Conversion in Healthcare & Life Sciences
-
Red Sea Shipping Disruptions Don’t Have Pharma Companies Seeing Red Just Yet
Generic drugs are the pharmaceutical products mainly affected by the missile attacks disrupting shipping in the Red Sea. While the extra costs borne by drug companies aren’t causing an immediate spike in product prices, experts say they’ll eventually be factored into prices if the attacks become a long-term problem.
-
A Startup’s Flexibility With ADC Cancer Drugs Attracts €128M for Clinical Trials
Tubulis’s next-generation ADC cancer drugs are designed to overcome limitations of currently available therapies in this drug class. The new financing will support clinical trial plans, but first, preclinical proof-of-concept data will be presented during the American Association for Cancer Research annual meeting.
-
AstraZeneca Acquisition Brings Drug to Fill a Rare Disease Gap Left by Takeda
AstraZeneca is acquiring Amolyt Pharma to get eneboparatide, a drug in Phase 3 development for treating hypoparathyroidism. Takeda Pharmaceutical markets the only FDA-approved treatment for this rare disease, but the Japanese pharmaceutical giant plans to stop making the drug.
-
Novartis Pays $90M for Molecules That Could Take STING Out of Inflammation
Placing research in the hands of a large pharmaceutical company is a goal of many biotech companies. IFM Therapeutics has now done it three times and its latest deal is the second time Novartis is the acquirer.
-
Schizophrenia Trial Failure Ends Acadia’s Efforts to Expand Use of Its Flagship Drug
With pimavanserin’s Phase 3 failure in schizophrenia, Acadia Pharmaceuticals said it will no longer run clinical trials for the drug, whose lone approval is for treating psychosis from Parkinson’s disease. The FDA previously rebuffed regulatory submissions for the drug in dementia and Alzheimer’s disease.
-
Boehringer Ingelheim Places €25M Bet on Sosei’s Novel Approach to Schizophrenia
Sosei Heptares’ schizophrenia drug candidate addresses a novel, difficult-to-drug target for neurological disorders. Boehringer Ingelheim can exercise its option on the small molecule following a Phase 1 test expected to yield data in 2025.
-
Blockbuster BeiGene Cancer Drug Adds Another FDA Approval
The FDA approved BeiGene’s Brukinsa as a treatment for advanced cases of follicular lymphoma. It’s the fifth FDA nod for the drug, which has become BeiGene’s top-selling product.
-
After ALS Drug Fails in Phase 3, Amylyx Weighs Pulling the Product From Market
Amylyx Pharmaceuticals co-CEO Justin Klee previously said the company would withdraw ALS drug Relyvrio from the market if it failed its Phase 3 clinical trial. The biotech has set an eight-week timeline to evaluate its next steps.
-
Novo Nordisk Obesity Pill Flashes the Potential to Beat Wegovy in Weight Loss
Novo Nordisk reported its weight loss pill amycretin led to greater weight loss measured at 12 weeks compared to clinical trial results for its blockbuster obesity drug Wegovy. But these results are from a small Phase 1 study and more testing is needed.
-
Gilead Sciences Signs Yet Another R&D Alliance for Multi-Target Cancer Therapies
Gilead Sciences’ partnership with Merus could yield novel antibody drugs capable of binding to three targets simultaneously. The alliance follows a collaboration that Gilead started last year with Tentarix Biotherapeutics, a startup also developing antibodies that bind to multiple targets.
-
FDA Approves Sandoz Biosimilars for Two Blockbuster Amgen Bone Drugs
Sandoz drugs Jubbonti and Wyost are approved for use in all indications covered by the Amgen products, Prolia and Xgeva. But no launch date is planned yet, due to ongoing patent litigation between the two companies.